Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy
Authors:
- H.‐S. YuHYH.‐S. Yu
- W.‐C. LiWLW.‐C. Li
- Y.‐C. KoYKY.‐C. Ko
- G.‐S. ChenGCG.‐S. Chen
- C.‐S. WuCWC.‐S. Wu
- Y.‐W. LuYLY.‐W. Lu
- Y.‐H. YangYYY.‐H. Yang
- C.‐C.E. LanCLC.‐C.E. Lan
- 15 June 2012
- journal article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 27 (7) , 876-883
Abstract
Background Psoriasis is a systemic disease associated with metabolic disorders and vascular complications. Both psoriasis and metabolic disorders are associated with systemic inflammation. We hypothesized that the sequence of events between the onset of psoriasis and metabolic disorder may affect the risk for subsequent development of vascular complications.Methods Nested case–control study was performed using the Taiwan National Health Insurance database. Accordingly, a total of 8180 psoriatic patients and 163 600 controls were included. Psoriasis was considered as the initiator of inflammatory march if metabolic disorder, including hypertension, diabetes mellitus and dyslipidemia, developed after onset of psoriasis. In patients with pre‐existing metabolic disorder, psoriasis was considered as the amplifier of inflammatory march.Results In patients whose psoriasis served as the disease initiator, a lower risk for developing vascular disease (HR = 1.49; 95% CI = 1.11–2.00 and HR = 1.64; 95% CI = 1.31–2.05 for cerebrovascular and cardiovascular events, respectively) was found compared with patients whose psoriasis served as the disease amplifier (HR = 2.26; 95% CI = 1.72–2.97 and HR = 2.78; 95% CI = 2.26–3.42 for cerebrovascular and cardiovascular events, respectively) after adjusting for age and gender. In terms of treatment implications, methotrexate was associated with reduced risk for developing cerebrovascular event (HR = 0.22; 95% CI = 0.05–0.88) only in patients with psoriasis serving as the disease amplifier.Conclusions Our results suggested that two scenarios of systemic inflammatory marches are present among psoriatic patients with metabolic disorder and judicious use of methotrexate may reduce the risk of cerebrovascular event, especially when psoriasis served as the disease amplifier of the systemic inflammatory march.Keywords
This publication has 23 references indexed in Scilit:
- Methotrexate Reduces the Occurrence of Cerebrovascular Events among Taiwanese Psoriatic Patients: A Nationwide Population-based StudyActa Dermato-Venereologica, 2012
- Age- and gender-specific population attributable risks of metabolic disorders on all-cause and cardiovascular mortality in TaiwanBMC Public Health, 2012
- Lung Cancer and Incidence of StrokeStroke, 2011
- The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidityExperimental Dermatology, 2011
- Effective continuous systemic therapy of severe plaque‐type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational studyJournal of the European Academy of Dermatology and Venereology, 2011
- Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population‐based sampleJournal of the European Academy of Dermatology and Venereology, 2010
- Psoriasis: depression, anxiety, smoking, and drinking habitsDermatologic Therapy, 2010
- Inflammation and metabolic disordersNature, 2006
- Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspectiveJournal of the American Academy of Dermatology, 2006
- Psoriatic patients with arthropathy show significant expression of free HLA class I heavy chains on circulating monocytes: a potential role in the pathogenesis of psoriatic arthropathyBritish Journal of Dermatology, 2004